The approach allows for more confident identification of peptide variants and enables deeper and broader peptide coverage, according to the researchers.
The UK startup believes protein PTMs can provide insights into protein damage that can be used to address common late-onset conditions like atherosclerosis.
Enthusiasm for dried blood spot samples is building among clinical proteomic researchers and companies, but recent work suggests technical hurdles remain.
The API assets could enable more data-intensive, machine learning-based approaches to healthcare, said a principal at DiscernDx investor Khosla Ventures.
The proteomics firm is swapping 4 million of its shares for a 10 percent interest in CPR with the goal of moving into clinical trials and related research.
The firm posted revenues of $530.5 million, with organic growth at 4 percent and acquisitions and currency effects adding 4 percent and 5 percent, respectively.
Developed by researchers at the University of Michigan, the software could help drive uptake of ion mobility mass spec within the top-down proteomics field.
At the JP Morgan conference, Thermo discussed new additions to its sequencing business, a clinical mass spec that will launch this year, and progress in China.
High-throughput DIA mass spec workflows for PTM analysis could allow researchers to, for instance, do more extensive characterization of cell signaling.
Researchers found that 98 percent of the identifications the system provided were correct, indicating the usefulness of the platform in clinical mycology.
The company entered an agreement with JP Morgan Chase that provides a five-year unsecured $300 million term loan and a $1.5 billion revolving facility.
The work demonstrates the ability of mass spectrometry to profile protein complexes in their native states in great detail and with relatively high throughput.
The method from University of Texas researchers combines carbamylation of proteins prior to trypsin digestion with ultraviolet photodissociation mass spec.
The system can measure dozens of markers at the single-cell level and, one researcher said, could aid studies of cellular heterogeneity in diseases like cancer.
Waters experienced some sluggishness in the US market in the quarter, and the firm noted that its pharma business, in particular, had seen a shift toward Europe.
A review by Max Planck researcher Matthias Mann and colleagues suggests that improved mass spec performance could enable more effective plasma marker discovery.
